Cargando…

Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy

BACKGROUND: Comorbidities are reportedly related to the survival of patients with non-small cell lung cancer (NSCLC). The purpose of this study was to explore the impact of comorbidity, assessed by the Charlson comorbidity index (CCI) and the simplified comorbidity scores (SCS) on clinical outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Xianghua, Zhu, Shicong, Xu, Cheng, Wang, Zhongyu, Su, Xingxing, Zeng, Dong, Long, Haixia, Zhu, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2020
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496511/ https://www.ncbi.nlm.nih.gov/pubmed/32893263 http://dx.doi.org/10.12659/MSM.922576

Ejemplares similares

Poor glycemic control might compromise the efficacy of chemotherapy in non‐small cell lung cancer patients with diabetes mellitus
por: Zeng, Xianghua, et al.
Publicado: (2019)

Influence of Hypertension on the Survival of Non-Small Cell Lung Cancer Patients with Type 2 Diabetes Mellitus
por: Zeng, Xianghua, et al.
Publicado: (2020)

Tumor-associated myeloid cells in cancer immunotherapy
por: Cheng, Xinyu, et al.
Publicado: (2023)

Serial ultra‐deep sequencing of circulating tumor DNA reveals the clonal evolution in non‐small cell lung cancer patients treated with anti‐PD1 immunotherapy
por: Li, Li, et al.
Publicado: (2019)

A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors
por: Wang, Zhiyi, et al.
Publicado: (2023)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors
por: Barham, Whitney, et al.
Publicado: (2023)

Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
por: Zhu, Zhouting, et al.
Publicado: (2023)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
por: Nahar, Kazi J, et al.
Publicado: (2020)

Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
por: Sahni, Sakshi, et al.
Publicado: (2018)

CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
por: Xiao, Minglu, et al.
Publicado: (2022)

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
por: Hao, Chunyan, et al.
Publicado: (2017)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
por: Li, Yanping, et al.
Publicado: (2023)

Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Brito, Angelo Borsarelli Carvalho, et al.
Publicado: (2021)

Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors
por: Zhao, Xinmin, et al.
Publicado: (2022)

Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy
por: Chin, K., et al.
Publicado: (2017)

Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
por: Machiraju, Devayani, et al.
Publicado: (2021)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
por: Fu, Yuyin, et al.
Publicado: (2021)

m(6)A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
por: Wang, Yunzhen, et al.
Publicado: (2023)

DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Zhu, Zhongling, et al.
Publicado: (2018)

Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma
por: Guo, Rui, et al.
Publicado: (2016)

The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer
por: Sheng, Zhixin, et al.
Publicado: (2017)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
por: Dantoing, Edouard, et al.
Publicado: (2021)

The role of exosomal PD-L1 in tumor immunotherapy
por: Wang, Jing, et al.
Publicado: (2021)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review
por: Li, Bin, et al.
Publicado: (2020)

Achievement of long-term local control after radiation and anti-PD-1 immunotherapy in locally advanced non-small cell lung cancer
por: Jing, Zhao, et al.
Publicado: (2021)

Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials
por: Ramos-Esquivel, Allan, et al.
Publicado: (2017)

COVID-19 vaccination is associated with enhanced efficacy of anti-PD-(L)1 immunotherapy in advanced NSCLC patients: a real-world study
por: Qian, Yunfei, et al.
Publicado: (2023)

The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives
por: Rocco, Danilo, et al.
Publicado: (2020)

The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma
por: Fang, Xia, et al.
Publicado: (2017)

Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy
por: Liu, Can, et al.
Publicado: (2018)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Antitumor effects of targeting myeloid-derived suppressive cells
por: Zeng, Dong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4gn6ulgbljfjvq9j354tvtjes5